IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.

ABSTRACT:

Background

The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed.

Objective

To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease.

Methods

58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution o

SUBMITTER: Petrzalka M 

PROVIDER: S-EPMC9236235 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature